(Q38207336)

31 August 2017

title

Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer (English)

1 reference

Theodorus H Van der Kwast

31 August 2017

main subject

personalized medicine

1 reference

1 reference

1 reference

Alejandro Berlin

2

0 references

object named as

Theodorus van der Kwast

series ordinal

4

0 references

Robert G. Bristow

object named as

Robert G Bristow

series ordinal

3

0 references

author name string

Michael Fraser

series ordinal

1

1 reference

31 August 2017

language of work or name

1 reference

24 April 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

33

1 reference

31 August 2017

issue

2

1 reference

31 August 2017

page(s)

85-94

1 reference

Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Pretreatment predictors of time to cancer specific death after prostate specific antigen failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

The timing of salvage radiotherapy after radical prostatectomy: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Management of metastatic castration-resistant prostate cancer: recent advances

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

How to select the optimal therapy for early-stage prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Active surveillance for prostate cancer: overview and update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Integrative genomic profiling of human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Concepts of epigenetics in prostate cancer development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Marked heterogeneity of ERG expression in large primary prostate cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Comprehensive molecular portraits of human breast tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Defining the threshold for significant versus insignificant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

mRNA expression signature of Gleason grade predicts lethal prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Clonal progression of prostate cancers from Gleason grade 3 to grade 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Punctuated evolution of prostate cancer genomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Development and validation of a 32-gene prognostic index for prostate cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

The genomic complexity of primary human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

The mutational landscape of lethal castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Correlation of ERG Expression and DNA Methylation Biomarkers with Adverse Clinicopathologic Features of Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Altered DNA Methylation Landscapes of Polycomb-Repressed Loci Are Associated with Prostate Cancer Progression and ERG Oncogene Expression in Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Massive genomic rearrangement acquired in a single catastrophic event during cancer development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Patterns of somatic mutation in human cancer genomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Somatic mutations affect key pathways in lung adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

The genomic landscapes of human breast and colorectal cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

An integrated genomic analysis of human glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Recurring mutations found by sequencing an acute myeloid leukemia genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

IDH1 and IDH2 mutations in gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

IDH mutation status in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Somatic alterations contributing to metastasis of a castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Personalized oncology through integrative high-throughput sequencing: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

Tracking the clonal origin of lethal prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.10.020

10.1016/J.UROLONC.2013.10.020

7 January 2021

Identifiers

DOI

1 reference

31 August 2017

1 reference